Evogene to Collaborate with Vilmorin for Tomato Yield Improvement
Evogene Ltd. announced a collaboration with Vilmorin, a French seed breeder and the mother company of 'Hazera Genetics', to improve yield and yield stability in tomatoes. Under the agreement, Evogene has licensed to Vilmorin the rights to certain genes discovered by Evogene, which have demonstrated improved yield and yield stability in tomatoes. The financial terms of the agreement were not disclosed.
The candidate genes licensed to Vilmorin under this collaboration were discovered by Evogene using its advanced in-silico gene discovery technology, the 'ATHLETE'. These genes have already undergone three years of field trials in tomatoes, displaying consistent improvements in yield of over 20% under both normal and environmental stress conditions. Through the collaboration, Vilmorin will evaluate the influence of the licensed genes on yield improvement in its elite varieties.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Revealing the Invisible Enemy - The coronavirus model developed by the Coronavirus Structural Task Force is the most exact model developed in the world to date
United_States_Assistant_Secretary_for_Health
Changes in the NHS have had the greatest impact in the pharma market over the last year - Pharmaceutical companies must become more strategic to capitalise on new
CV Therapeutics Submits New Drug Application For Regadenoson
With chemical modification, stable RNA nanoparticles go 3-D
Graffinity and Mutabilis announce second research collaboration - Drug Discovery Collaboration to Focus on Infectious Disease Targets
DEINOVE partners with VTT Technical
Labcyte Receives 19th and 20th Patents for Acoustic Droplet Ejection Applications
Almac’s Clinical Technologies Division undergoes successful joint GCP-GMP MHRA Inspection
Lab21 - a new kind of company - Antiviral drug discovery services and clinical trials support
